LUMICKS Revenue and Competitors
Estimated Revenue & Valuation
- LUMICKS's estimated annual revenue is currently $33M per year.
- LUMICKS's estimated revenue per employee is $154,000
Employee Data
- LUMICKS has 214 Employees.
- LUMICKS grew their employee count by -24% last year.
LUMICKS's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head Sales & Customer Success | Reveal Email/Phone |
3 | Head Marketing and Business Development | Reveal Email/Phone |
4 | VP Sales DSM | Reveal Email/Phone |
5 | Assistant Officer | Reveal Email/Phone |
6 | Global Information Technology Director | Reveal Email/Phone |
7 | Warehouse and Logistics Support Officer | Reveal Email/Phone |
8 | Commercial Director - Immuno-Oncology | Reveal Email/Phone |
9 | Field Operations & Manufacturing Manager | Reveal Email/Phone |
10 | Product Design Manager | Reveal Email/Phone |
LUMICKS Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $33M | 214 | -24% | N/A | N/A |
#2 | $1.5M | 18 | -18% | N/A | N/A |
#3 | $2.8M | 29 | -6% | N/A | N/A |
#4 | $2.6M | 27 | -13% | N/A | N/A |
#5 | $27.9M | 181 | N/A | N/A | N/A |
#6 | $0.2M | 3 | N/A | N/A | N/A |
#7 | $4.7M | 42 | 8% | N/A | N/A |
#8 | $1.2M | 14 | -18% | N/A | N/A |
#9 | $0.6M | 9 | -61% | N/A | N/A |
#10 | $5.2M | 46 | 0% | N/A | N/A |
What Is LUMICKS?
LUMICKS brings to market revolutionary single-molecule technologies that enable for the first time visualization of molecular interactions and acoustic manipulation of biomolecules. These breakthroughs are allowing scientists to understand life to the smallest detail, which is critical for cancer research and drug development. Current single-molecule techniques allow scientists to achieve only partial understanding of complex biological processes. With LUMICKS groundbreaking optical tweezer-fluorescence microscopy, scientists are now able to visualize and measure mechanical properties of biomolecular complexes in real time, revealing the complete picture. Manipulation, force measurements and visualization of these complexes, for example DNA-protein interactions, are performed simultaneously, which allows correlation of mechanical properties to the number, location and conformational state of proteins bound to DNA. LUMICKS provides ready-to-use instrumentation for single-molecule visualization, acoustic manipulation of biomolecules and microfluidic flow systems, allowing scientists to focus on their experiments and breakthrough science.
keywords:N/A
N/A
Total Funding
214
Number of Employees
$33M
Revenue (est)
-24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
LUMICKS News
AMSTERDAM, April 21, 2022 /PRNewswire/ -- LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule...
LUMICKS is a leading life science tools company that develops equipment for Dynamic Single-Molecule and Cell Avidity analysis, two rapidly...
Lumicks, a developer of single-molecule analysis technologies for cancer research and immunotherapy, has raised a $93 million Series D. Farallon Capital Management and Lauxera Capital Partners led the round, which the startup will use for research and development and to invest in its commercial ...
With an exponential increase in the rate of progress in biological research, the demand to understand how biological processes occur at a molecular level is becoming increasingly important. And, according to Amsterdam-based Lumicks, it wants to make a difference by unlocking the power of Dynamic ...
Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding. The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with par ...
Other Companies in Amsterdam
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $49.4M | 214 | 32% | N/A |
#2 | $48.7M | 216 | 1% | N/A |
#3 | $64.4M | 217 | 3% | N/A |
#4 | $54.4M | 218 | 8% | N/A |
#5 | $50.6M | 219 | 39% | N/A |